Today's Date: June 9, 2023
USCIB Releases Pride Month Statement, Supporting Equality and Inclusion   •   Children's Miracle Network Hospitals® Celebrates 40th Anniversary with Celebrity Friends and Supporters   •   Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematol   •   Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023   •   A New Era of Three-Row Luxury: The First-Ever Lexus TX   •   TIO EQUITY ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages Tingo Group, Inc. Investors with Losses in Excess of $100K to Secur   •   BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congres   •   Perfuze Announces Appointment of New Chair of the Board   •   SoftwareReviews Reveals the Top ESG Software Solutions That Enable Organizations to Build a Culture of Purpose and Sustainabilit   •   Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presen   •   Saudi Arabia: Modern means of transportation for easier Hajj   •   Hengtong Optic-Electric Releases 2022 ESG Report at the PT Expo   •   Fairmont Mayakoba to host exclusive 2023 pride celebration   •   IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy   •   Providing LGBTQI+ people with a safe home in Canada   •   Ventas Realty, Limited Partnership Announces Upsize and Pricing of $750 Million of Exchangeable Senior Notes   •   ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at   •   CGTN: China stresses green development, ethnic unity in modernization drive   •   Stallergenes Greer Showcases Clinical Relevance and Persisting Benefits of Its Allergen Immunotherapy Treatments at 2023 EAACI C   •   Sophisticated Utility Vehicle: all-new 2024 Lexus GX Redefines SUV
Bookmark and Share

Cure Rare Disease Welcomes Leading Experts to Scientific Advisory Board

WOODBRIDGE, Conn. , March 20 /Businesswire/ - Cure Rare Disease (CRD) - a nonprofit biotechnology company focused on developing treatments for ultra-rare diseases - announces the appointment of leading experts in the fields of gene therapy and neuromuscular disorders to its Scientific Advisory Board (SAB).

As part of their role, SAB members help advance CRD's preclinical and clinical development of its gene therapy and antisense oligonucleotide (ASO) programs, providing strategic advice on scientific, regulatory, and clinical matters.

The members of the newly appointed SAB bring a wealth of expertise and experience in the areas of treatment and therapeutic development for neuromuscular diseases. They include:

  • Nick Johnson, M.D., M.Sci., FAAN (Board Chair)

    Adult Neurology, Neuromuscular Vice Chair, Research Associate Professor, VCU School of Medicine
  • Carsten Bonnemann, M.D.

    Senior Investigator, Neuromuscular and Neurogenetic Disorders of Childhood Section, NIH Intramural Research Program
  • Elizabeth McNally, M.D., Ph.D.

    Professor and Director, Center for Genetic Medicine Professor of Medicine

    (Cardiology) and Biochemistry and Molecular Genetics, Northwestern Feinberg School of Medicine
  • Perry Shieh, M.D., PhD

    Neurology, Neuromuscular Medicine, UCLA Health
  • Alan Beggs, Ph.D.

    Director, The Manton Center for Orphan Disease Research

    Sir Edwin and Lady Manton Professor of Pediatrics, Harvard Medical School

"CRD is honored to welcome these esteemed experts in gene therapy and neuromuscular disorders to our scientific advisory board," said Rich Horgan, MBA, Founder and CEO of CRD. "Their insights and guidance will be critical as we continue to advance our programs and work towards our goal of providing life-saving treatments to individuals with rare diseases."

CRD currently has 19 therapeutic programs under development, including potential treatments for Duchenne muscular dystrophy, Limb Girdle muscular dystrophy, SCA3 and ADSSL1 distal myopathy, as well as a program aimed at overcoming the challenges of neutralizing antibodies in gene therapy delivery. Collectively, these programs offer pragmatic hope of treatment to more than 200,000 Americans living with rare and ultra-rare diseases.

About Cure Rare Disease

Cure Rare Disease (CRD) is a nonprofit biotechnology company focused on the development of genetic medicines for rare and ultra- rare diseases. CRD is committed to accelerating the development of treatments for individuals with rare diseases through a patient-centric approach to research and development. The company's programs include gene therapy and antisense oligonucleotide (ASO) treatments for a range of rare diseases. For more information, please visit

STORY TAGS: Infectious Diseases, Neurology, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Nonprofit, Personnel, Connecticut, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News